Breast Cancer, Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Conditions
Keywords
PTK787, Metastatic breast cancer, Refractory gynecological cancer
Brief summary
The main purpose of this study is to see if the study drug, PTK787, is safe and to find the highest dose that can be given safely without causing serious side effects.
Detailed description
* Patients will come to the clinic once a week to receive study treatment. To help reduce the chance of an allergic reaction patients will take Decadron tablets orally the night before, the morning of and the evening of receiving chemotherapy. * The lead-in schedule of dosing is as follows: Day 1: Taxotere intravenously; Day 4: PTK787 orally; Day 14: Taxotere and PTK787. * After the lead-in schedule, a cycle will consist of 28 days. PTK787 will be given orally once a day without interruption. Taxotere will be given on Day 1, Day 8, Day 15 and Day 22. * Before each dose of Taxotere, blood tests, urine tests, and a physical exam will be done. A radiological evaluation will be done every two months. If the patients tumor remains stable or shrinks in size, they may continue to stay on the study. * Patients should not eat grapefruit or drink grapefruit juice during this study.
Interventions
DRUGDocetaxel
Participants may continue receiving study drug as long as their disease does not worsen
DRUGPTK787
Participants may continue receiving study drug as long as their disease does not worsen
Sponsors
Brigham and Women's Hospital
Massachusetts General Hospital
Dana-Farber Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Recurrent gynecological cancers or metastatic breast cancer. Initial diagnosis must be confirmed histologically. * Measurable disease or nonmeasurable disease * Age \> 18 years * ECOG performance 0,1,2 * 4 weeks or greater since major surgery, 3 weeks or greater since chemotherapy * Certain lab values * Negative for proteinuria
Exclusion criteria
* Four or more treatment regimens * History or presence of uncontrolled CNS disease * Prior biologic or immunotherapies less than 3 weeks prior to registration * Prior full field radiotherapy less than 4 weeks or limited field radiotherapy less than 2 weeks prior to registration * Prior therapy with anti-VEGF agents * Peripheral neuropathy with functional impairment \> CTC grade 2 * Pregnant or breast feeding * Concurrent severe and/or uncontrolled medical condition * Chronic renal disease * Acute or chronic liver disease * Impairment of gastrointestinal function or GI disease * Confirmed diagnosis of HIV infection are excluded at the investigators discretion * Therapeutic warfarin sodium or similar oral anticoagulants that are metabolized by the cytochrome p450 system.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the maximum tolerated dose and the dose limiting toxicity of weekly Taxotere patients treated with PTK787. | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| To estimate the preliminary efficacy of this combination in both metastatic breast cancer patients and refractory gynecological patients. | 2 years |
Countries
United States
Outcome results
None listed